eddingpharm

Eddingpharm Acquires Small Molecule Drug Assets From ACT Biotech

Eddingpharm has signed an asset purchase agreement with ACT Biotech to acquire worldwide rights to its three small molecule drug assets Telatinib, ACTB1003 and ACTB1010.

Ablynx Grants Eddingpharm License To Develop Anti-RANKL Nanobody

Ablynx has granted a license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody, ALX-0141, in China, Hong Kong, Macau and Taiwan.

GSK, Eddingpharm To Collaborate On Novel Breast Cancer Drug In China

China's Eddingpharm will launch GSK's new drug for advanced or metastatic breast cancer in China.